You are here
TARGAZYME, INC.
https://www.targazyme.com
UEI: NJG4X7NZ4BM1
# of Employees: 5
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD
Amount: $1,526,626.00DESCRIPTION provided by applicant Allogeneic hematopoietic stem cell transplant has the potential to cure various hematological malignancies and inherited disorders but is limited by treatment rel ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Therapeutic Potential and Targeted Homing of ECSOD-MSCs in Animal Model of Mucositi
Amount: $224,932.00DESCRIPTION (provided by applicant): In the present submission we are requesting funding to support studies designed to assess proof-of-concept for a novel cell-based approach that possesses the poten ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Novel cell-based Restorative Approach in Treatment of Diabetes-related Retinopath
Amount: $215,739.00DESCRIPTION (provided by applicant): Retinal vascular diseases remain a common cause of vision loss and blindness with diabetes as the most common condition leading to retinopathy in adults in Western ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Increased Therapeutic Potential of Migrating Neural Stem Cells and ASC101 Treatment
Amount: $335,440.00DESCRIPTION (provided by applicant): Multiple sclerosis (MS) affects 1 in 1000 individuals in the US and is characterized by progressive sensory, motor and cognitive impairments. These functional defi ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
ASC101 Enhancement of Regenerative Capacity of Amniotic Fluid-derived Stem Cells
Amount: $156,754.00DESCRIPTION (provided by applicant): In the present STTR we propose to investigate two novel approaches in our exploration of the therapeutic and regenerative potential of cell-based medicine. Further ...
STTRPhase I2012Department of Health and Human Services National Institutes of Health -
Enhanced Engraftment with Fucosylation of Cord Blood and Mesenchymal Stem Cells
Amount: $290,908.00DESCRIPTION (provided by applicant): Three primary sources of hematopoietic stem cells (HSCs) are routinely used in HSC therapy. These include mobilized peripheral blood, bone marrow and umbilical cor ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Ex Vivo Fucosylation of Cord Blood with FTVII and Enhanced Hematopoietic Recovery
Amount: $347,580.00DESCRIPTION (provided by applicant): The three primary sources of hematopoietic stem cells (HSCs) for bone marrow transplant are: mobilized peripheral blood, bone marrow, and umbilical cord. While eac ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Novel Approach to Enhance Cord Blood-Mediated Bone Marrow Homing and Engraftment
Amount: $193,658.00DESCRIPTION (provided by applicant): Despite significant recent government and private-sector efforts to improve the current state of the art in bone marrow transplants, many patients still suffer fro ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Standard Robot Platform Designed for Unstructured Environment Research
Amount: $74,516.00Robotic researchers currently are using insufficient and varying robot platforms to investigate issues crucial to the successful development of a remote reconnaissance tool for the urban search and re ...
SBIRPhase I2004Department of Commerce National Institute of Standards and Technology -
Multidisciplinary Design Opimization (MDO)
Amount: $548,902.00A Cartesian, multigrid, Euler solver is investigated for development as a module suitable for the multidisciplinary design optimization (MDO) environment. The ultimate objective is not to improve the ...
SBIRPhase II1996Department of Defense Air Force
